{
    "Trade/Device Name(s)": [
        "Total Bilirubin"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K150510",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121985"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG",
        "MQM"
    ],
    "Summary Letter Date": "March 2, 2015",
    "Summary Letter Received Date": "March 3, 2015",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1110",
        "21 CFR 862.1113"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system",
        "Bilirubin (total and unbound) in the neonate test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum (glass)",
        "Serum Separator Tube (SST)",
        "EDTA tube",
        "Lithium heparin tube",
        "Lithium heparin Plasma Separator Tube (PST)",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c8000 System"
    ],
    "Method(s)/Technology(ies)": [
        "End-point colorimetric",
        "Diazo reaction"
    ],
    "Methodologies": [
        "Colorimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Laboratories Total Bilirubin assay using colorimetric diazo method on ARCHITECT c8000 System",
    "Indications for Use Summary": "Quantitation of total bilirubin in human serum or plasma of adults and neonates on the ARCHITECT c8000 System; used in diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, and to aid in indicating risk of bilirubin encephalopathy in newborns.",
    "fda_folder": "Clinical Chemistry"
}